SAN FRANCISCO — Surrozen Inc., a company discovering and developing novel antibodies for regenerative medicine, has completed a $50 million Series B financing. The financing included new investors Horizons Ventures, Hartford HealthCare Endowment, and NS Investment. The Column Group, and other existing investors, also participated.
The new funding will be used to advance the Company’s antibody discovery and development programs in liver disease, and to expand the Company’s therapeutic platform into additional disease areas where Wnt modulation has therapeutic potential. Surrozen has developed two proprietary antibody platforms that can function as Wnt or R-spondin mimetics, respectively, in stimulating cell and organ-specific tissue regeneration.
“Since its founding in 2016, Surrozen has made significant advances in understanding the cell-specific effects of modulating Wnt signaling with bi-specific molecules,” said Craig Parker, CEO of Surrozen. “With that understanding, we have developed two novel antibody-based technologies that have recently been validated in multiple disease models. The proceeds of the Series B financing will allow us to advance optimized drug candidates into development for advanced liver disease and one other disease area. Surrozen will also explore applications of the technology in multiple other disease areas.”
Added Tim Kutzkey, PhD, Board Chairman and Managing Partner at The Column Group, “In launching Surrozen, we merged deep expertise and breakthrough discoveries by our Scientific Founders in the fields of Wnt biology, receptor-ligand structural biology, and protein engineering, driven by a mission to discover and develop novel, proprietary regenerative medicines with broad clinical utility. The Column Group is excited by the company’s progress and continues to enthusiastically support Surrozen’s growth and vision as it advances innovative programs into development.”